The Department of Defense has unveiled a new initiative to screen service members for low testosterone levels, marking a significant expansion of hormone therapy access within the military. Defense Secretary Pete Hegseth announced the program, emphasizing its role in enhancing military readiness and long-term health. This move comes amidst ongoing debates about the administration’s stance on hormone therapy, particularly for transgender service members.
The program will offer annual testosterone testing for service members aged 30 and older, with voluntary testing available for younger troops. Those diagnosed with a deficiency may receive testosterone replacement therapy if recommended by a medical provider. Hegseth framed the initiative as a means to restore and optimize natural capabilities, rather than artificially enhance performance.
Contrasting Approaches to Hormone Therapy
The Pentagon’s new program highlights a stark contrast in the administration’s approach to hormone therapy. While testosterone replacement therapy is now being promoted as evidence-based care for cisgender service members, access to gender-affirming hormone therapy for transgender individuals remains restricted. The Trump administration has previously cited medical costs as a reason for limiting transgender healthcare, despite spending significantly more on other treatments.
In 2026, U.S. District Judge Ana Reyes blocked the administration’s policy restricting transgender healthcare, noting that the military spent roughly $41 million on Viagra in 2026 alone. The judge described the cost of transgender care as so small in relation to total military spending that it was not even a rounding error. The new testosterone screening program further underscores this disparity in treatment.
Political and Medical Context
The initiative is part of a broader political focus on testosterone levels, with other administration officials advocating for easier access to hormone replacement therapies. Health Secretary Robert F. Kennedy Jr. has spoken about using testosterone as part of his personal anti-ageing regimen. However, medical experts caution that blanket testing for low testosterone is not typically recommended, as levels can fluctuate throughout the day.
The American Urological Association emphasized that a diagnosis of low testosterone should not be based on a single blood test alone. Instead, it should involve symptoms and two separate tests. The association appreciated the administration’s understanding of the importance of screening but stressed the need for comprehensive evaluation.
Scrutiny and Controversy
The move has drawn attention from advocates for transgender rights, who point out the inconsistency in the administration’s policies. Rep. Pramila Jayapal highlighted the disparity, noting that the same hormone therapy is being provided to cisgender service members while being denied to transgender individuals. This contradiction raises questions about the underlying motivations for these policies.
Additionally, the program has sparked discussions about the broader implications of hormone therapy in the military. Some experts have raised concerns about the potential for misuse or overdiagnosis, particularly given the aggressive marketing of testosterone treatments online. The Pentagon’s initiative will likely face further scrutiny as it is implemented and its effects become clearer.
